PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.

被引：0

作者：

Lo Russo, Giuseppe

Ganzinelli, Monica

Sgambelluri, Francesco

Galli, Francesca

Prelaj, Arsela

Manglaviti, Sara

Bottiglieri, Achille

Di Mauro, Rosa Maria

Ferrara, Roberto

Dumitrascu, Andra Diana

Sottotetti, Elisa

Martinetti, Antonia

Fabbri, Alessandra

Rulli, Eliana

De Braud, Filippo G.

Torri, Valter

Garassino, Marina Chiara

Anichini, Andrea

Proto, Claudia

Mortarini, Roberta

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Thorac Oncol Unit, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[4] IRCCS Ist Ric Farmacol Mario Negri, Milan, Italy

[5] Ist Nazl Tumori, Milan, Italy

[6] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy

[7] NCI, Milan, Italy

[8] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy

[9] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, ENETS Ctr Excellence, Milan, Italy

[10] Univ Milan, Oncol & Hemato Oncol Dept, Milan, Italy

[11] Mario Negri Inst Pharmacol Res IRCCS, Milan, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9033

引用

页数：1

共 50 条

[41] Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
Guo, Wen-Zhi
Li, Lu-Hao
Qiao, Shishi
Li, Ren-Feng
Zhang, Weijie
He, Wei
Su, Chang
Pan, Jie
Jin, Shui-Ling
Zong, Hong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] The preliminary data from a single-arm, open- label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Zhao, Y.
Huang, Y.
Fang, W.
Yang, Y.
Shi, J.
Zhao, H.
Meng, X.
Zhang, L.
Liu, A.
Xu, T.
Liu, Y.
Wang, N.
Zhang, L.
ANNALS OF ONCOLOGY, 2023, 34
[43] Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
Hirano, Hidekazu
Takahashi, Naoki
Amanuma, Yusuke
Suzuki, Nobumi
Takahari, Daisuke
Kawakami, Takeshi
Kudo-Saito, Chie
Nagashima, Kengo
Boku, Narikazu
Kato, Ken
Shoji, Hirokazu
BMC CANCER, 2025, 25 (01)
[44] Single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: Preliminary results of a phase II randomized trial
Gridelli, C.
Reck, M.
Gregorc, V.
Migliorino, M.
Muller, T. R.
Manegold, C.
Favaretto, A.
Crucitta, E.
Munoz, M.
Cirri, L.
Marini, L.
Rossi, A.
Koschel, G.
ANNALS OF ONCOLOGY, 2005, 16 : 162 - 162
[45] First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Descourt, Renaud
Greillier, Laurent
Perol, Maurice
Ricordel, Charles
Auliac, Jean-Bernard
Falchero, Lionel
Gervais, Radj
Veillon, Remi
Vieillot, Sabine
Guisier, Florian
Marcq, Marie
Justeau, Gregoire
Bigay-Game, Laurence
Bernardi, Marie
Fournel, Pierre
Doubre, Helene
Pinsolle, Julian
Amrane, Karim
Chouaid, Christos
Decroisette, Chantal
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (01) : 91 - 99
[46] Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial
Zhang, Zhiye
Meng, Xiangrui
Yang, Xiuli
Hong, Yong-Gui
Xia, Jin
Chen, Yunfang
Wu, Tao
Shan, Zheng-Zheng
Fan, Qingxia
Wang, Feng
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study)
Renaud Descourt
Laurent Greillier
Maurice Perol
Charles Ricordel
Jean-Bernard Auliac
Lionel Falchero
Radj Gervais
Rémi Veillon
Sabine Vieillot
Florian Guisier
Marie Marcq
Grégoire Justeau
Laurence Bigay-Game
Marie Bernardi
Pierre Fournel
Hélène Doubre
Julian Pinsolle
Karim Amrane
Christos Chouaïd
Chantal Decroisette
Cancer Immunology, Immunotherapy, 2023, 72 : 91 - 99
[48] First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark, Michael Thomas
Froesch, Patrizia
Gysel, Katrin
Rothschild, Sacha
Addeo, Alfredo
Ackermann, Christoph J.
Chiquet, Sabrina
Schneider, Martina
Ribi, Karin
Maranta, Angela Fischer
Bastian, Sara
Von Moos, Roger Anton Fredy
Joerger, Markus
Fruh, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17
Mark, M.
Froesch, P.
Gysel, K.
Rothschild, S.
Addeo, A.
Ackermann, C.
Chiquet, S.
Schneider, M.
Ribi, K.
Fischer, A.
Bastian, S.
von Moos, R.
Joerger, M.
Frueh, M.
SWISS MEDICAL WEEKLY, 2023, 153 : 7S - 7S
[50] TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
Okamoto, I.
Kuyama, S.
Girard, N.
Lu, S.
Franke, F. A.
Pan, E.
Ren, N.
Chen, A.
Oputa, E.
Lisberg, A. E.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →